Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects

British Journal of Clinical Pharmacology

Volumn 59, Issue 5, 2005, Pages 495-510

  Dumont, G J H ^a   De Visser, S J ^a   Cohen, A F ^a   Van Gerven, J M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Biomarker; Phase I; SSRIs

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE; ZIMELDINE;

ALPHA RHYTHM; ATTENTION; AUDITORY SYSTEM; CENTRAL NERVOUS SYSTEM FUNCTION; DOSE RESPONSE; DRUG EFFECT; ELECTROENCEPHALOGRAM; EYE MOVEMENT; HUMAN; HUMAN EXPERIMENT; MEDLINE; MEMORY; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; PRIORITY JOURNAL; REM SLEEP; REVIEW; SLEEP; THETA RHYTHM; VISUAL SYSTEM; VISUOMOTOR COORDINATION;

BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MENTAL PROCESSES; NERVOUS SYSTEM PHYSIOLOGY; NEUROPSYCHOLOGICAL TESTS; SEROTONIN UPTAKE INHIBITORS;

EID: 18244370235     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02342.x     Document Type: Review

References (78)

1. de Visser SJ, van der Post J, Pieters MSM, Cohen AF, van Gerven JMA. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001; 51: 119-32.
2. de Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven JMA. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 2003; 55: 39-50.
3. Spreen, O, Strauss, E. A compendium of neuropsychological tests; Administration, norms, and commentary. Second Edition. 1998. New York, Oxford University Press, Inc.
4. Bond, AJ. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974; 47: 211-18.
5. Herrmann, WM. International Pharmaco EEG Group (IPEG). Recommendations for EE G and evoked potential mapping. Neuropsychobiol 1989; 22: 170-6.
6. Rijnbeek, B, de Visser, SJ, Franson, KL, Cohen, AF, and van Gerven, JMA. REM sleep reduction as a biomarker for the effects of antidepressants in healthy volunteers. J Psychopharmacol 2003; 17 (2): 196-203.
7. Nakazawa Y, Kotorii M, Kotorii T, Ohshima M, Hasuzawa H. Individual variations in response of human REM sleep to amitriptyline and haloperidol. Electroencephalogr Clin Neurophysiol 1977; 42: 769-75.
8. Cowen PJ, Sargent PA. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 1997; 11: 345-8.
9. Ogura C, Kishimoto A, Mizukawa R, Matsubayashi M, Omura F, Kunimoto N. Comparative study of the effects of 9 antidepressants on several physiological parameters in healthy volunteers. Neuropsychobiology 1987; 17: 139-44.
10. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, See WR. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 1991; 14: 439-47.
11. Sharpley AL, Williamson DJ, Attenburrow ME, Pearson G, Sargent P, Cowen PJ. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 1996; 126: 50-4.
12. Riemann D, Veithaus S, Laubenthal S, Muller WE, Berger M. REM-suppressing effects of amitriptyline and amitriptyline-N-oxide after acute medication in healthy volunteers: results of two uncontrolled pilot trials. Pharmacopsychiatry 1990; 23: 253-8.
13. Schlosser R, Roschke J, Rossbach W, Benkert O. Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. Eur Neuropsychopharmacol 1998; 8: 273-8.
14. Nicholson AN, Pascoe PA. 5-Hydroxytryptamine and noradrenaline uptake inhibition: studies on sleep in man. Neuropharmacology 1986; 25: 1079-83.
15. Green JF, King DJ, Trimble KM. Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam. J Psychopharmacol 2000; 14: 30-6.
16. Hindmarch I, Bhatti JZ. Psychopharmacological effects of sertraline in normal, healthy volunteers. Eur J Clin Pharmacol 1988; 35: 221-23.
17. Saletu B, Grunberger J, Linzmayer L. On central effects of serotonin re-uptake inhibitors: quantitative EEG and psychometric studies with sertraline and zimelidine. J Neural Transm 1986; 67: 241-66.
18. Ilic TV, Korchounov A, Ziemann U. Complex modulation of human motor cortex excitability by the specific serotonin re-uptake inhibitor sertraline. Neurosci Lett 2002; 319: 116-20.
19. Seifritz E, Baumann P, Muller MJ et al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996; 14: 253-63.
20. Itil TM, Menon GN, Bozak MM, Itil KZ. CNS effects of citalopram, a new serotonin inhibitor antidepressant (a quantitative pharmaco- electroencephalography study). Prog Neuropsychopharmacol Biol Psychiatry 1984; 8: 397-409.
21. Nathan PJ, Sitaram G, Stough C, Silberstein RB, Sali A. Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Behav Pharmacol 2000; 11: 639-42.
22. Clemmesen L, Jensen E, Min SK, Bolwig TG, Rafaelsen OJ. Salivation after single-doses of the new antidepressants femoxetine, mianserin and citalopram. A cross-over study. Pharmacopsychiatry 1984; 17: 126-32.
23. Penttila J, Syvalahti E, Hinkka S, Kuusela T, Scheinin H. The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 2001; 154: 343-9.
24. Lader M, Melhuish A, Frcka G, Fredricson OK, Christensen V. The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol 1986; 31: 183-90.
25. Liechti ME, Geyer MA, Hell D, Vollenweider FX. Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 2001; 24: 240-52.
26. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Rojdmark S. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 2000; 56: 123-27.
27. Tse WS, Bond AJ. Serotonergic involvement in the psychosocial dimension of personality. J Psychopharmacol 2001; 15: 195-8.
28. Rammsayer T. Dopaminergic and serotoninergic influence on duration discrimination and vigilance. Pharmacopsychiatry 1989; 22 (Suppl 1): 39-43.
29. d'Ardhuy XL, Boeijinga PH, Renault B et al. Effects of serotonin-selective and classical antidepressants on the auditory P300 cognitive potential. Neuropsychobiology 1999; 40: 207-13.
30. Ramaekers JG, Muntjewerff ND, O'Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995; 39: 397-404.
31. Monteleone P, Orazzo C, Natale M, Maj M. Lack of effect of short-term fluoxetine administration on nighttime plasma melatonin levels in healthy subjects. Biol Psychiatry 1994; 35: 139-42.
32. McGuirk J, Silverstone T. The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obes 1990; 14: 361-72.
33. Parise G, Bosman MJ, Boecker DR, Barry MJ, Tarnopolsky MA. Selective serotonin reuptake inhibitors: Their effect on high-intensity exercise performance. Arch Phys Med Rehabil 2001; 82: 867-71.
34. Wilson SJ. effects of 5 weeks of administration of fluoxetine and dotheipin in normal volumteers on sleep, daytime sedation, psychomotor performance and mood. J Psychopharmacol 2002; 16: 321. j. psychopharmacology.
35. Gelfin Y, Gorfine M, Lerer B. Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am J Psychiatry 1998; 155: 290-2.
36. McGuirk J, Silverstone T. The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obes 1990; 14: 361-72.
37. Ramaekers JG, Muntjewerff ND, O'Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995; 39: 397-404.
38. Bonne O, Krausz Y, Aharon Y, Gelfin Y, Chisin R, Lerer B. Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers. Psychopharmacology (Berl) 1999; 143: 24-8.
39. Demisch K, Demisch L, Nickelsen T, Rieth R. The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine. J Neural Transm 1987; 68: 257-70.
40. Hasbroucq T, Rihet P, Blin O, Possamai CA. Serotonin and human information processing: fluvoxamine can improve reaction time performance. Neurosci Lett 1997; 229: 204-8.
41. Phillips MA, Bitsios P, Szabadi E, Bradshaw CM. Comparison of the antidepressants reboxetine, fluvoxamine and amitriptyline upon spontaneous pupillary fluctuations in healthy human volunteers. Psychopharmacology (Berl) 2000; 149: 72-6.
42. Linnoila M, Stapleton JM, George DT, Lane E, Eckardt MJ. Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. J Clin Psychopharmacol 1993; 13: 175-80.
43. Flett SR, Szabadi E, Bradshaw CM. A comparison of the effects of fluvoxamine and amitriptyline on autonomic functions in healthy volunteers. Eur J Clin Pharmacol 1992; 42: 529-33.
44. Wilson WH, Higano H, Papadatos Y, Kelwala S, Ban TA. A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers. Br J Clin Pharmacol 1983; 15 (Suppl 3): 385S-392S.
45. Curran HV, Shine P, Lader M. Effects of repeated doses of fluvoxamine, mianserin and placebo on memory and measures of sedation. Psychopharmacology (Berl) 1986; 89: 360-3.
46. Rihet P, Hasbroucq T, Blin O, Possamai CA. Serotonin and human information processing: an electromyographic study of the effects of fluvoxamine on choice reaction time. Neurosci Lett 1999; 265: 143-6.
47. Saletu B, Grunberger J, Rajna P. Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine. Br J Clin Pharmacol 1983; 15 Suppl 3): 369S-383S.
48. Saletu B, Grunberger J, Anderer P, Linzmayer L, Zyhlarz G. Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry. J Neural Transm 1996; 103: 191-216.
49. Demisch K, Demisch L, Nickelsen T, Rieth R. The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine. J Neural Transm 1987; 68: 257-70.
50. Ochs HR, Greenblatt DJ, Verburg-Ochs B, Labedski L. Chronic treatment with fluvoxamine, clovoxamine, and placebo: interaction with digoxin and effects on sleep and alertness. J Clin Pharmacol 1989; 29: 91-5.
51. Spigset O, Mjorndal T. Effect of fluvoxamine on platelet 5-HT2A receptors as studied by [3H]lysergic acid diethylamide ([3H]LSD) binding in healthy volunteers. Psychopharmacology (Berl) 1997; 133: 39-42.
52. Spigset O, Mjorndal T. The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status. J Clin Psychopharmacol 1997; 17: 292-7.
53. van Laar MW, van Willigenburg AP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995; 15: 30-40.
54. Frewer U, Lader M. The effects of nefazodone, imipramine and placebo, alone and combined with alcohol, in normal subjects. Int Clin Psychopharmacol 1993; 8: 13-20.
55. Wilson WM, Maughan RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 1992; 77: 921-4.
56. Parise G, Bosman MJ, Boecker DR, Barry MJ, Tarnopolsky MA. Selective serotonin reuptake inhibitors: Their effect on high-intensity exercise performance. Arch Phys Med Rehabil 2001; 82: 867-71.
57. Nathan PJ, Norman TR, Burrows GD. Nocturnal plasma melatonin concentrations in healthy volunteers: effect of single doses of d-fenfluramine, paroxetine, and ipsapirone. J Pineal Res 1996; 21: 55-8.
58. Kerr JS, Fairweather DB, Mahendran R, Hindmarch I. The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. Int Clin Psychopharmacol 1992; 7: 101-8.
59. Bitsios P, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology (Berl) 1999; 143: 286-92.
60. Deijen JB, Orlebeke JF, Loriaux SM, de Vries J. The effects of paroxetine and maprotiline on mood, perceptual-motor skills, and eye movements in healthy volunteers. Acta Psychiatr Scand Suppl 1989; 350: 41.
61. Robbe HW, O'Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995; 5: 35-42.
62. Brauer LH, Rukstalis MR, de Wit H. Acute subjective responses to paroxetine in normal volunteers. Drug Alcohol Depend 1995; 39: 223-30.
63. Schlosser R, Wetzel H, Dorr H, Rossbach W, Hiemke C, Benkert O. Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers. Psychoneuroendocrinology 2000; 25: 377-88.
64. Roschke J, Kogel P, Schlosser R et al. Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Psychopharmacology (Berl) 1997; 132: 44-9.
65. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68: 435-42.
66. Schmitt JA, Kruizinga MJ, Riedel WJ. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 2001; 15: 173-9.
67. Gordon C, Whale R, Cowen PJ. Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology (Berl) 1998; 137: 201-2.
68. Tranter R, Healy H, Cattell D, Healy D. Functional effects of agents differentially selective to noradrenergic or serotonergic systems. Psychol Med 2002; 32: 517-24.
69. Longmore J, Banjar W, Bradshaw CM, Szabadi E. Effects of a controlled-release formulation of trazodone on psychomotor and autonomic functions in healthy volunteers: comparison with trazodone (conventional formulation), amitriptyline and placebo. Eur J Clin Pharmacol 1988; 34: 97-9.
70. Semlitsch HV, Anderer P, Saletu B, Binder GA, Decker KA. Acute effects of the novel antidepressant venlafaxine on cognitive event-related potentials (P300), eye blink rate and mood in young healthy subjects. Int Clin Psychopharmacol 1993; 8: 155-66.
71. O'Hanlon JF, Robbe HW, Vermeeren A, van Leeuwen C, Danjou PE. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 1998; 18: 212-21.
72. Saletu B, Grunberger J, Anderer P, Linzmayer L, Semlitsch HV, Magni G. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Br J Clin Pharmacol 1992; 33: 589-601.
73. Patat A, Troy S, Burke J et al. Absolute bioavailability and electroencephalographic effects of conventional and extended-release release formulations of venlafaxine in healthy subjects. J Clin Pharmacol 1998; 38: 256-67.
74. O'Hanlon JF, Robbe HW, Vermeeren A, van Leeuwen C, Danjou PE. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 1998; 18: 212-21.
75. Rudorfer MV, Scheinin M, Karoum F, Ross RJ, Potter WZ, Linnoila M. Reduction of norepinephrine turnover by serotonergic drug in man. Biol Psychiatry 1984; 19: 179-193.
76. von Knorring L, Mornstad H. Saliva secretion rate and saliva composition as a model to determine the effect of antidepressant drugs on cholinergic and noradrenergic transmission. Neuropsychobiology 1986; 15: 146-54.
77. Knorring L, Mornstad H, Forsgren L, Holmgren S. Acute effects of different antidepressant drugs on saliva secretion and accommodation range. Pharmacopsychiatry 1986; 19: 106-10.
78. Linnoila M, Johnson J, Dubyoski K, Buchsbaum MS, Schneinin M, Kilts C. Effects of antidepressants on skilled performance. Br J Clin Pharmacol 1984; 18 (Suppl 1): 109S-120S.